The 2018 EHRA* practical guide on non–vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation (AF) walks clinicians through 20 topics of clinical scenarios, including stroke management, NOAC use in conditions other than AF, and when to measure plasma levels. [Eur Heart J 2018; doi.org/10.1093/eurheartj/ehy136]
Real-world studies on patients with atrial fibrillation (AF) show that dabigatran is safe with low bleeding and stroke rates when used for long term (over 2 years) or used continuously in patients undergoing cardiovascular (CV) interventions, according to phase II results of the prospective, observational, global registry programme GLORIA-AF* presented at the EHRA 2018 Annual Congress.
An algorithm to help stratify patients with syncope requiring hospitalization vs those that can be discharged from the emergency department (ED) safely forms part of the new European Society Cardiology (ESC) syncope guidelines launched at the EHRA 2018 meeting.
Continuous apixaban seems equally safe as warfarin and other vitamin K antagonists (VKAs) during atrial fibrillation (AF) ablation in patients at risk for stroke, according to the AXAFA–AFNET* 5 trial presented at EHRA 2018.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Doctor - Malaysia digital copy today!
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.